Breast cancer with a germline BRCA1/2 mutation (gBRCAm) is sensitive to DNA-damaging therapies, such as platinum therapies and poly (ADP-ribose) polymerase (PARP) inhibitors. This evidence concerns the gene BRCA1 and breast cancer.